This content is provided by Scott M. Lassman.
Scott Lassman has nearly 30 years’ experience in FDA law and policy, both as an in-house attorney and in private practice. He provides strategic advice and advocacy to small, mid-size and large pharmaceutical, biotechnology and medical device companies, as well as the trade associations that represent them and the investors who fund them. His practice covers all aspects of FDA regulatory law, with a special focus on exclusivity, biosimilars, product approval and policy matters.
JD, University of Virginia School of Law, 1991 (Order of the Coif); MA, University of Texas at Austin, 1988, BA, Yale University, 1985 (cum laude).
